Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 20,125-20,136 of 23,847
Drug study icon
TerminatedNCT01677182

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolarity type I

This study exists to explore whether the medication Ramelteon could improve care and understanding. Researchers are trying to understand whether the medication Ramelteon can give earlier or clearer feedback during care.

Multiple locations, including Birmingham
BipolarityDrugA study involving a medication or substance.From 18 Years to 75 Years
Countries
United States, United Kingdom, Bulgaria, ...
Sponsor
Takeda
Condition
Bipolarity
Behavioral study icon
CompletedNCT02604407

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether the medication SHP465 offers something meaningfully different. Researchers are trying to understand how people respond to the medication SHP465 in practice and what may need to be adjusted.

Multiple locations, including Encino
ADHDBehavioralFrom 18 Years to 55 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Behavioral study icon
CompletedNCT02466425

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether the medication SHP465 offers something meaningfully different. Researchers are trying to understand how people respond to the medication SHP465 in practice and what may need to be adjusted.

Multiple locations, including Dothan
ADHDBehavioralFrom 6 Years to 17 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Drug study icon
WithdrawnNCT05372887

Safety study of TNX-102 SL in PTSD

This study was withdrawn in Kenya. It is testing TNX-102 SL for PTSD.

In Nairobi
PTSDDrugFrom 18 Years to 75 Years
Countries
Kenya
Sponsor
Tonix Pharmaceuticals, Inc.
Condition
PTSD
Drug study icon
CompletedNCT00060489

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Depression for depression in bipolarity

This study is completed in the United States. It is testing Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Depression for depression in bipolarity.

Multiple locations, including Birmingham
Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
AstraZeneca
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT00697515

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether the medication Lisdexamfetamine offers something meaningfully different. Researchers are trying to understand what the medication Lisdexamfetamine could change in day-to-day care and decision-making.

Multiple locations, including Little Rock
ADHDDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Drug study icon
CompletedNCT00280566

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolarity type I (Manic or Mixed)

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

Multiple locations, including Birmingham
BipolarityDrugOver 18 Years
Countries
United States, France, Chile, ...
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Bipolarity
Drug study icon
CompletedNCT02411526

Safety and PK study With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

In Long Beach
SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
Zogenix, Inc.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.